Comparison of Efficacy and Safety Outcomes of Generic Versus Original Fingolimod Products in Patients with Multiple Sclerosis from Buenos Aires, Argentina

被引：0
|
作者：
Chertcoff, Anibal [1 ]
Steinberg, Judith [1 ]
Carra, Adriana [1 ]
机构：
[1] Hosp Britan Buenos Aires, MS & Demyelinating Dis, Buenos Aires, DF, Argentina
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2847
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy and safety of alemtuzumab versus fingolimod in RRMS patients after switch from natalizumab: a retrospective analysis
    Pfeuffer, S.
    Ruck, T.
    Kleinschnitz, C.
    Wieshuber, M.
    Lee, D-H.
    Linker, R.
    Doerck, S.
    Straeten, V.
    Windhagen, S.
    Aufenberg, C.
    Lang, M.
    Christian, E.
    Tackenberg, B.
    Wiendl, H.
    Meuth, S. G.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 334 - 335
  • [42] Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina
    Ignacio Rojas, Juan
    Patrucco, Liliana
    Alonso, Ricardo
    Garcea, Orlando
    Deri, Norma
    Carnero Contentti, Edgar
    Lopez, Pablo A.
    Pablo Pettinicchi, Juan
    Caride, Alejandro
    Cristiano, Edgardo
    [J]. CLINICAL NEUROPHARMACOLOGY, 2022, 45 (03) : 45 - 51
  • [43] Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
    Lefort, M.
    Sharmin, S.
    Andersen, J. B.
    Vukusic, S.
    Casey, R.
    Debouverie, M.
    Edan, G.
    Ciron, J.
    Ruet, A.
    De Seze, J.
    Maillart, E.
    Zephir, H.
    Labauge, P.
    Defer, G.
    Lebrun-Frenay, C.
    Moreau, T.
    Berger, E.
    Clavelou, P.
    Pelletier, J.
    Stankoff, B.
    Gout, O.
    Thouvenot, E.
    Heinzlef, O.
    Al-Khedr, A.
    Bourre, B.
    Casez, O.
    Cabre, P.
    Montcuquet, A.
    Wahab, A.
    Camdessanche, J. P.
    Maurousset, A.
    Ben Nasr, H.
    Hankiewicz, K.
    Pottier, C.
    Maubeuge, N.
    Nifle, C.
    Laplaud, D. A.
    Horakova, D.
    Dimitri-Boulos, D.
    Havrdova, E. K.
    Alroughani, R.
    Izquierdo, G.
    Eichau, S.
    Ozakbas, S.
    Patti, F.
    Onofrj, M.
    Lugaresi, A.
    Terzi, M.
    Grammond, P.
    Grand'Maison, F.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [44] Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
    M. Lefort
    S. Sharmin
    J. B. Andersen
    S. Vukusic
    R. Casey
    M. Debouverie
    G. Edan
    J. Ciron
    A. Ruet
    J. De Sèze
    E. Maillart
    H. Zephir
    P. Labauge
    G. Defer
    C. Lebrun-Frenay
    T. Moreau
    E. Berger
    P. Clavelou
    J. Pelletier
    B. Stankoff
    O. Gout
    E. Thouvenot
    O. Heinzlef
    A. Al-Khedr
    B. Bourre
    O. Casez
    P. Cabre
    A. Montcuquet
    A. Wahab
    J. P. Camdessanché
    A. Maurousset
    H. Ben Nasr
    K. Hankiewicz
    C. Pottier
    N. Maubeuge
    D. Dimitri-Boulos
    C. Nifle
    D. A. Laplaud
    D. Horakova
    E. K. Havrdova
    R. Alroughani
    G. Izquierdo
    S. Eichau
    S. Ozakbas
    F. Patti
    M. Onofrj
    A. Lugaresi
    M. Terzi
    P. Grammond
    F. Grand’Maison
    [J]. BMC Medical Research Methodology, 22
  • [45] Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes
    Gulec, Bade
    Everest, Elif
    Gorkey, Ogeday Derin
    Koc, Metehan
    Tutuncu, Melih
    Saip, Sabahattin
    Siva, Aksel
    Uygunoglu, Ugur
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, : 2745 - 2751
  • [46] Evaluating the Safety and Efficacy of Transitioning Multiple Sclerosis Patients from Natalizumab to Rituximab
    Ziemssen, Tjalf
    Albrecht, Holger
    Haas, Judith
    Klotz, Luisa
    Lang, Michael
    Lassek, Chrstoph
    Schmidt, Stephan
    Tackenberg, Bjorn
    Cornelissen, Christian
    [J]. NEUROLOGY, 2016, 86
  • [47] Efficacy and safety of Fingolimod therapy in multi-ethnic Malaysian patients with relapsing remitting multiple sclerosis: A longitudinal observational study
    Viswanathan, S.
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2018, 54 : 25 - 28
  • [48] Changes in immune cell profile, clinical and safety outcomes in fingolimod-treated patients with relapsing multiple sclerosis in the FLUENT study
    Mao-Draayer, Yang
    Cohen, Jeffrey A.
    Bar-Or, Amit
    Han, May H.
    Singer, Barry
    Jaitly, Nina
    Kolodny, Scott
    Elam, Chelsea
    Meng, Xiangyi
    Ziehn, Marina
    Cree, Bruce A. C.
    [J]. NEUROLOGY, 2020, 94 (15)
  • [49] Changes in Immune Cell Profile, Clinical and Safety Outcomes in Fingolimod-Treated Patients With Relapsing Multiple Sclerosis in the FLUENT Study
    Mao-Draayer, Y.
    Cohen, J. A.
    Bar-Or, A.
    Han, M. H.
    Singer, B.
    Jaitly, N.
    Kolodny, S.
    Elam, C.
    Meng, X.
    Ziehn, M.
    Cree, B. A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 40 - 41
  • [50] Efficacy and Tolerability of Fingolimod, Dimethylfumarate, and Teriflunomide in Patients with Multiple Sclerosis: Real World Experience from a Single Center
    NgocHanh Vu
    Bradshaw, Michael
    Moses, Harold
    Sriram, Subramaniam
    Pawate, Siddharama
    [J]. NEUROLOGY, 2016, 86
12345